Samsung Biologics, Checkpoint Therapeutics Expand Cosibelimab Mfg. Pact

Samsung Biologics and Checkpoint Therapeutics, Inc. have expanded a long-term manufacturing partnership for Checkpoint's anti-PD-L1 antibody, cosibelimab. Building upon an existing contract manufacturing agreement entered into in 2017, Samsung Biologics will provide additional commercial-scale drug substance manufacturing for Checkpoint and will begin manufacturing in 2021 in Plant 1.

"We look forward to continuing our manufacturing partnership with Samsung Biologics for our lead product candidate, cosibelimab, currently in a pivotal clinical trial for metastatic cutaneous squamous cell carcinoma. Checkpoint is on track to report full topline results from the pivotal trial in mid-2021," said James F. Oliviero, President and Chief Executive Officer of Checkpoint. "This agreement provides Checkpoint access to a top-tier manufacturing site for the long-term commercial supply of cosibelimab after potential regulatory approvals worldwide."

"We are extremely proud of this extended partnership with Checkpoint to support our client and make an impact by helping broader patient populations in need," said Dr. Tae Han Kim, CEO of Samsung Biologics. "As a reliable contract development and manufacturing organization ("CDMO") service provider, Samsung Biologics offers the highest quality manufacturing for Checkpoint to assist in its endeavor to bring innovative treatments for patients all around the globe."

Samsung Biologics recently announced it will break ground on its fourth plant this year to commence manufacturing activities in the latter half of 2022.